Completed PHASE3 INTERVENTIONAL 2-arm NCT00363376

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

A Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Sponsor: Eli Lilly and Company

Interventions Sugar Pill (placebo) Zonisamide olanzapine zonisamide

Updated 6 times since 2017 Last updated: Apr 11, 2012 Started: Jan 31, 2008 Primary completion: Feb 28, 2011 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Weight Gain, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Lindner Center of HOPE
University of Cincinnati

Data source: Lindner Center of HOPE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mason, United States